- Published on
Psychological Terms — Amylobarbitone
Amylobarbitone is a short-acting barbiturate classified as a central nervous system depressant. Chemically known as amylobarbital, it was formerly widely prescribed as a sedative and hypnotic agent to assist with sleep initiation and anxiety reduction. Like other barbiturates, it works by enhancing inhibitory GABAergic transmission, thereby producing a calming effect and decreasing overall neural excitability.
In clinical settings, amylobarbitone was historically used for insomnia, pre-operative sedation, and occasionally for managing agitation. Its rapid onset and moderate duration made it appealing for short-term therapeutic use. However, barbiturates carry a high risk of dependence, tolerance, and overdose, especially when combined with other depressants such as alcohol. Because of these dangers, their medical use has dramatically declined and been largely replaced by benzodiazepines, which generally have safer therapeutic windows.
Outside legitimate medical contexts, amylobarbitone has occasionally been taken as a street drug, valued for its sedating and euphoric effects. It has also appeared in legal literature concerning forensic contexts, including its rare historical association with “narcoanalysis,” in which sedatives were administered to lower inhibitions during interrogation—an approach now considered unethical and scientifically unsupported.
Amylobarbitone may also be referred to by the proprietary name Amytal.
Amylobarbitone is a short-acting barbiturate classified as a central nervous system depressant. Chemically known as amylobarbital, it was formerly widely prescribed as a sedative and hypnotic agent to assist with sleep initiation and anxiety reduction. Like other barbiturates, it works by enhancing inhibitory GABAergic transmission, thereby producing a calming effect and decreasing overall neural excitability.
In clinical settings, amylobarbitone was historically used for insomnia, pre-operative sedation, and occasionally for managing agitation. Its rapid onset and moderate duration made it appealing for short-term therapeutic use. However, barbiturates carry a high risk of dependence, tolerance, and overdose, especially when combined with other depressants such as alcohol. Because of these dangers, their medical use has dramatically declined and been largely replaced by benzodiazepines, which generally have safer therapeutic windows.
Outside legitimate medical contexts, amylobarbitone has occasionally been taken as a street drug, valued for its sedating and euphoric effects. It has also appeared in legal literature concerning forensic contexts, including its rare historical association with “narcoanalysis,” in which sedatives were administered to lower inhibitions during interrogation—an approach now considered unethical and scientifically unsupported.
Amylobarbitone may also be referred to by the proprietary name Amytal.
0 Comments